COMMISSIONER FOR PATENTS

FORM PTO-2053-B (REV. 10/03) Approved for use through 07/31/2006.OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application of:

Blatt et al.

Application No.:

10/669,841

Filing Date:

September 23, 2003

Title:

Oligonucleotide Mediated Inhibition of

Hepatitis B Virus and Hepatitis C Virus

Replication

Direct to:

Mail Stop MISSING PARTS Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

NOTICE UNDER 37 CFR 1.251 – Pending Application

Statement (check the appropriate box):

The copy submitted with this reply is a complete and accurate copy of applicant's record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and applicant for the above-identified application that is not among applicant's records.

The copy of the paper(s) listed in the notice under 37 CFR 1.251 is/are a complete and accurate copy of applicant's record of such paper(s).

The papers produced by applicant are applicant's complete record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and the applicant for the above-identified application that is not among applicant's records.

Applicant does not possess any record of the correspondence between the Office and the applicant for the above-identified application.

Anita J. Terpstra, Ph.D.

Typed or printed name

A Copy of this notice should be returned with the reply.

Burden Hour Statement: This collection of information is required by 37 CFR 1.251. The information is used by the public to reply to a request for copies of correspondence between the applicant and the USPTO in order to reconstruct an application file. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 60 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

PTO-2053-B (Rev. 10/03)



PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. MBHB02-249-E (400/042US))

IN THE APPLICATION OF:)		
Blatt, et al.)		
Serial No.	10/669,841)	Examiner:	To Be Assigned
Filed:	September 23, 2003)	Group Art Unit:	To Be Assigned
Title '	Oligonucleotide Mediated Inhibition of Hepatitis B Virus and Hepatitis C Virus Replication)	Confirmation No.:	2643

REPLY TO NOTICE UNDER 37 C.F.R. §1.251

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attn Mr. James Murphy:

In reply to the Notice under 37 C.F.R. §1.251 mailed on December 21, 2004, Applicants hereby submit a copy of the following applications:

- (1). PCT/US02/09187
- **(2)**. WO96/18736
- WO99/49029 (3).
- (4).WO99/53050
- **(5)**. WO99/61631
- (6). WO00/63364

Tel: (312) 913-0001 Fax: (312) 913-0002 Application No. 10/669,841 Attorney Docket No. MBHB02-249-E (400/042US)

Applicants state that the copies of the applications listed herein are complete and accurate copies of Applicants' record of such applications (see statement attached herewith).

It is believed that no fee is due in connection with this Reply. If a fee is due, the Patent Office is authorized to charge deposit account number 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: February 4, 2005

Anita J. Terpstra

Registration No. 47,132





UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. MBHB02-249-E (400/042US))

IN THE APPLICATION OF:)		
D1	u)		
Blatt, et al.)		
Serial No.	10/669,841	ĺ	Examiner:	To Be Assigned
Filed:	September 23, 2003)	Group Art Unit:	To Be Assigned
Title	Oligonucleotide Mediated Inhibition of Hepatitis B Virus and Hepatitis C Virus Replication)))	Confirmation No.:	2643

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attn Mr. James Murphy:

In regard to the above identified application,

- 1. We are transmitting herewith the attached:
 - a) Reply to Notice Under 37 C.F.R. §1.251;
 - b) Copy Notice Under 37 CFR § 1.251 Pending Application (Form PTO-2053-B);
 - c) Copy of PCT/US02/09187, WO96/18736, WO99/49029, WO99/53050, WO99/61631, and WO00/63364; and
 - d) Return postcard
- 2. With respect to fees:
 - a) It is believed no fee is due at this time.
- GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 4, 2005.

Respectfully submitted

ву: Усил

Registration No. 47,132

Date: Febr

February 4, 2005